UA73355C2 - 5-chlorine-3(4-methanesulfonylphenyl)-6'-methyl-[2,3']pyridinyl in pure crystallyne shape and a method for synthesis - Google Patents

5-chlorine-3(4-methanesulfonylphenyl)-6'-methyl-[2,3']pyridinyl in pure crystallyne shape and a method for synthesis Download PDF

Info

Publication number: UA73355C2
Authority: UA; Ukraine
Prior art keywords: compound; mixture; methanesulfonylphenyl; crystallyne; pyridinyl
Prior art date: 2000-05-26

Application number

UA20021210537A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Merck & Co Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-05-26

Filing date

2001-05-22

Publication date

2005-07-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22772880&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA73355(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-05-22 Application filed by Merck & Co Inc filed Critical Merck & Co Inc

2005-07-15 Publication of UA73355C2 publication Critical patent/UA73355C2/uk

Links

238000000034 method Methods 0.000 title abstract description 13
230000015572 biosynthetic process Effects 0.000 title 1
125000004076 pyridyl group Chemical group 0.000 title 1
238000003786 synthesis reaction Methods 0.000 title 1
229940126062 Compound A Drugs 0.000 abstract description 18
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 abstract description 18
201000010099 disease Diseases 0.000 abstract description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
230000001404 mediated effect Effects 0.000 abstract description 3
108010037462 Cyclooxygenase 2 Proteins 0.000 abstract description 2
102000010907 Cyclooxygenase 2 Human genes 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
230000002194 synthesizing effect Effects 0.000 abstract 1
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 27
238000012986 modification Methods 0.000 description 18
230000004048 modification Effects 0.000 description 18
238000002844 melting Methods 0.000 description 15
230000008018 melting Effects 0.000 description 15
239000000203 mixture Substances 0.000 description 13
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 12
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
238000010438 heat treatment Methods 0.000 description 5
239000012265 solid product Substances 0.000 description 5
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
238000000113 differential scanning calorimetry Methods 0.000 description 4
238000001914 filtration Methods 0.000 description 4
239000007787 solid Substances 0.000 description 4
239000000243 solution Substances 0.000 description 4
239000000725 suspension Substances 0.000 description 4
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
239000012299 nitrogen atmosphere Substances 0.000 description 3
231100000252 nontoxic Toxicity 0.000 description 3
230000003000 nontoxic effect Effects 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
101000603223 Homo sapiens Nischarin Proteins 0.000 description 2
102100038995 Nischarin Human genes 0.000 description 2
238000002441 X-ray diffraction Methods 0.000 description 2
229940125904 compound 1 Drugs 0.000 description 2
229940125782 compound 2 Drugs 0.000 description 2
238000001816 cooling Methods 0.000 description 2
238000002129 infrared reflectance spectroscopy Methods 0.000 description 2
238000002955 isolation Methods 0.000 description 2
JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 2
229940011051 isopropyl acetate Drugs 0.000 description 2
GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 2
238000002156 mixing Methods 0.000 description 2
201000008482 osteoarthritis Diseases 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
239000000047 product Substances 0.000 description 2
LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 2
238000001291 vacuum drying Methods 0.000 description 2
SHXWCVYOXRDMCX-UHFFFAOYSA-N 3,4-methylenedioxymethamphetamine Chemical compound CNC(C)CC1=CC=C2OCOC2=C1 SHXWCVYOXRDMCX-UHFFFAOYSA-N 0.000 description 1
206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
206010006811 Bursitis Diseases 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
108010037464 Cyclooxygenase 1 Proteins 0.000 description 1
208000005171 Dysmenorrhea Diseases 0.000 description 1
206010013935 Dysmenorrhoea Diseases 0.000 description 1
201000005569 Gout Diseases 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
241000110847 Kochia Species 0.000 description 1
241001275944 Misgurnus anguillicaudatus Species 0.000 description 1
201000002481 Myositis Diseases 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 1
102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
208000025747 Rheumatic disease Diseases 0.000 description 1
208000036071 Rhinorrhea Diseases 0.000 description 1
206010039101 Rhinorrhoea Diseases 0.000 description 1
241000750042 Vini Species 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
239000013543 active substance Substances 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
239000000908 ammonium hydroxide Substances 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
230000000694 effects Effects 0.000 description 1
MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical group C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
206010022000 influenza Diseases 0.000 description 1
208000014674 injury Diseases 0.000 description 1
210000003041 ligament Anatomy 0.000 description 1
208000004296 neuralgia Diseases 0.000 description 1
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
238000000634 powder X-ray diffraction Methods 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000005855 radiation Effects 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
238000010992 reflux Methods 0.000 description 1
230000000552 rheumatic effect Effects 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
230000003637 steroidlike Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
201000004595 synovitis Diseases 0.000 description 1
WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
208000004371 toothache Diseases 0.000 description 1
230000008733 trauma Effects 0.000 description 1
230000009385 viral infection Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Physical Education & Sports Medicine (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Reproductive Health (AREA)
Oncology (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Pulmonology (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyridine Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

UA20021210537A 2000-05-26 2001-05-22 5-chlorine-3(4-methanesulfonylphenyl)-6'-methyl-[2,3']pyridinyl in pure crystallyne shape and a method for synthesis UA73355C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US20801700P	2000-05-26	2000-05-26
PCT/US2001/016566 WO2001092230A1 (fr)	2000-05-26	2001-05-22	5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- [2,3']bipyridinyl sous forme cristalline pure et procede de synthese

Publications (1)

Publication Number	Publication Date
UA73355C2 true UA73355C2 (en)	2005-07-15

Family

ID=22772880

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA20021210537A UA73355C2 (en)	2000-05-26	2001-05-22	5-chlorine-3(4-methanesulfonylphenyl)-6'-methyl-[2,3']pyridinyl in pure crystallyne shape and a method for synthesis

Country Status (49)

Country	Link
EP (1)	EP1296951B1 (fr)
JP (2)	JP3665053B2 (fr)
KR (1)	KR100757699B1 (fr)
CN (1)	CN1227233C (fr)
AR (1)	AR028577A1 (fr)
AT (1)	ATE483687T1 (fr)
AU (2)	AU2001264804B2 (fr)
BG (1)	BG65855B1 (fr)
BR (1)	BRPI0111140B8 (fr)
CA (1)	CA2410234C (fr)
CR (1)	CR6606A (fr)
CY (1)	CY1111440T1 (fr)
CZ (1)	CZ20023888A3 (fr)
DE (1)	DE60143197D1 (fr)
DK (1)	DK1296951T3 (fr)
EA (1)	EA004809B1 (fr)
EE (1)	EE05242B1 (fr)
EG (1)	EG24189A (fr)
ES (1)	ES2351958T3 (fr)
GC (1)	GC0000362A (fr)
GE (1)	GEP20053492B (fr)
GT (1)	GT200100091A (fr)
HK (1)	HK1058932A1 (fr)
HN (1)	HN2001000110A (fr)
HR (1)	HRP20020934B1 (fr)
HU (1)	HU228423B1 (fr)
IL (1)	IL152582A0 (fr)
IN (2)	IN2002CH02089A (fr)
IS (1)	IS2806B (fr)
JO (1)	JO2216B1 (fr)
MA (1)	MA26919A1 (fr)
ME (1)	ME00428B (fr)
MX (1)	MX230696B (fr)
MY (1)	MY123569A (fr)
NO (1)	NO324495B1 (fr)
NZ (1)	NZ522394A (fr)
PA (1)	PA8516901A1 (fr)
PE (1)	PE20011324A1 (fr)
PH (1)	PH12001001175B1 (fr)
PL (1)	PL358153A1 (fr)
PT (1)	PT1296951E (fr)
RS (1)	RS51541B (fr)
SI (1)	SI1296951T1 (fr)
SK (1)	SK287174B6 (fr)
SV (1)	SV2002000462A (fr)
TW (1)	TWI303634B (fr)
UA (1)	UA73355C2 (fr)
WO (1)	WO2001092230A1 (fr)
ZA (1)	ZA200209558B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE320809T1 (de) *	1999-11-29	2006-04-15	Merck Frosst Canada Inc	Polymorphe, amorphe und hydratisierte formen von 5-chlor-3-(methansulfonylphenyl)-6'-methyl-2, 3')bipyridinyl
US6858631B1 (en)	1999-11-29	2005-02-22	Merck & Co., Inc.	Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl
US6521642B2 (en) *	2000-05-26	2003-02-18	Merck & Co., Inc.	5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl in pure crystalline form and process for synthesis
BRPI1006374A2 (pt)	2009-02-27	2019-09-24	Cadila Healthcare Ltda	"processo para a preparação de etoricoxib, composto, processo para a purificação de etoricoxib, forma polimórfica, etoricoxib"
WO2012004677A1 (fr)	2010-07-05	2012-01-12	Actavis Group Ptc Ehf	Formes à l'état solide de sels d'étoricoxib
EP2714676B1 (fr)	2011-05-27	2019-04-24	Farma GRS, d.o.o.	Procédé pour la préparation de la forme polymorphe i de l'étoricoxib
WO2013105106A1 (fr)	2011-11-03	2013-07-18	Cadila Healthcare Limited	Procédé amélioré pour la préparation d'étoricoxibe et de polymorphes de celui-ci
WO2013075732A1 (fr)	2011-11-21	2013-05-30	Synthon Bv	Procédé de préparation d'une forme cristalline i de l'étoricoxib
EP2601952A1 (fr)	2011-12-07	2013-06-12	Zentiva, k.s.	Nouveaux sels et cocrristaux pharmaceutiqement acceptables du 5- chloro-3-(4-méthanesulfonylphényl)-6'-méthyl-[2,3'] bipyridinyle et leurs utilisations thérapeutiques
WO2014041558A2 (fr)	2012-08-27	2014-03-20	Glenmark Pharmaceuticals Limited; Glenmark Generics Limited	Procédé de préparation d'étoricoxib cristallin
WO2014033526A1 (fr)	2012-08-27	2014-03-06	Cadila Healthcare Limited	Compositions pharmaceutiques d'étoricoxib
CN104418799A (zh) *	2013-09-03	2015-03-18	天津药物研究院	一种依托考昔的晶型及其制备方法和应用
WO2015036550A1 (fr)	2013-09-13	2015-03-19	Synthon B.V.	Procédé pour la préparation d'étoricoxib
CN106632003B (zh) *	2015-12-31	2019-02-12	上海博志研新药物技术有限公司	一种依托考昔的制备方法
CN108069896B (zh) *	2016-11-11	2022-08-12	昆明积大制药股份有限公司	一种依托考昔晶型的制备方法
CN107417599B (zh) *	2017-06-21	2020-06-09	四川尚锐生物医药有限公司	一种依托考昔晶型的制备方法
CN107056691B (zh) *	2017-06-21	2020-03-10	四川尚锐生物医药有限公司	一种制备依托考昔晶型v的方法
MX2017009660A (es)	2017-07-26	2017-11-23	Laboratorios Liomont S A De C V	Composicion farmaceutica con un rango de relacion entre el clorhidrato de tramadol y el etoricoxib para su administracion para el tratamiento del dolor.
CN107556231A (zh) *	2017-09-23	2018-01-09	江苏正大清江制药有限公司	一种依托考昔与对硝基苯甲酸形成的盐的晶型及制备方法
CN107417600A (zh) *	2017-09-26	2017-12-01	江苏正大清江制药有限公司	一种依托考昔与呋喃甲酸形成盐的新晶型及制备方法
CN107898787B (zh) *	2017-12-15	2018-11-30	扬子江药业集团上海海尼药业有限公司	一种药物组合物及其制剂和制备方法
MX2018013070A (es)	2017-12-29	2019-10-15	Gruenenthal Gmbh	Combinación farmacéutica que comprende clorhidrato de tramadol de liberación extendida y etoricoxib de liberación inmediata, y su uso para el tratamiento del dolor.
CN110143915A (zh) *	2019-06-03	2019-08-20	蚌埠学院	一种依托考昔与对甲苯磺酸形成盐的新晶型及制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5593994A (en) *	1994-09-29	1997-01-14	The Dupont Merck Pharmaceutical Company	Prostaglandin synthase inhibitors
US5739166A (en) *	1994-11-29	1998-04-14	G.D. Searle & Co.	Substituted terphenyl compounds for the treatment of inflammation
EE03680B1 (et) *	1996-07-18	2002-04-15	Merck Frosst Canada & Co. / Merck Frosst Canada &Cie.	Asendatud püridiinid, nende kasutamine ja farmatseutilised kompositsioonid
US5861419A (en) *	1996-07-18	1999-01-19	Merck Frosst Canad, Inc.	Substituted pyridines as selective cyclooxygenase-2 inhibitors
RS49945B (sr) *	1998-04-24	2008-09-29	Merck & Co.Inc.,	Postupak za sintetizovanje inhibitora cox-2
ATE320809T1 (de) *	1999-11-29	2006-04-15	Merck Frosst Canada Inc	Polymorphe, amorphe und hydratisierte formen von 5-chlor-3-(methansulfonylphenyl)-6'-methyl-2, 3')bipyridinyl

2001
- 2001-05-15 PH PH12001001175A patent/PH12001001175B1/en unknown
- 2001-05-16 GC GCP20011369 patent/GC0000362A/en active
- 2001-05-16 AR ARP010102327A patent/AR028577A1/es unknown
- 2001-05-16 TW TW090111718A patent/TWI303634B/zh not_active IP Right Cessation
- 2001-05-17 PE PE2001000443A patent/PE20011324A1/es not_active Application Discontinuation
- 2001-05-18 MY MYPI20012375 patent/MY123569A/en unknown
- 2001-05-21 GT GT200100091A patent/GT200100091A/es unknown
- 2001-05-22 JO JO200179A patent/JO2216B1/en active
- 2001-05-22 EP EP01939267A patent/EP1296951B1/fr not_active Expired - Lifetime
- 2001-05-22 ME MEP-2008-638A patent/ME00428B/me unknown
- 2001-05-22 PL PL01358153A patent/PL358153A1/xx not_active Application Discontinuation
- 2001-05-22 HU HU0302336A patent/HU228423B1/hu unknown
- 2001-05-22 GE GE5012A patent/GEP20053492B/en unknown
- 2001-05-22 CZ CZ20023888A patent/CZ20023888A3/cs unknown
- 2001-05-22 RS YUP-894/02A patent/RS51541B/sr unknown
- 2001-05-22 NZ NZ522394A patent/NZ522394A/en not_active IP Right Cessation
- 2001-05-22 SK SK1670-2002A patent/SK287174B6/sk not_active IP Right Cessation
- 2001-05-22 AT AT01939267T patent/ATE483687T1/de active
- 2001-05-22 AU AU2001264804A patent/AU2001264804B2/en not_active Expired
- 2001-05-22 IL IL15258201A patent/IL152582A0/xx active IP Right Grant
- 2001-05-22 KR KR20027015871A patent/KR100757699B1/ko active Protection Beyond IP Right Term
- 2001-05-22 WO PCT/US2001/016566 patent/WO2001092230A1/fr active IP Right Grant
- 2001-05-22 AU AU6480401A patent/AU6480401A/xx active Pending
- 2001-05-22 ES ES01939267T patent/ES2351958T3/es not_active Expired - Lifetime
- 2001-05-22 PA PA20018516901A patent/PA8516901A1/es unknown
- 2001-05-22 CA CA002410234A patent/CA2410234C/fr not_active Expired - Lifetime
- 2001-05-22 DK DK01939267.9T patent/DK1296951T3/da active
- 2001-05-22 PT PT01939267T patent/PT1296951E/pt unknown
- 2001-05-22 SI SI200130982T patent/SI1296951T1/sl unknown
- 2001-05-22 BR BR0111140-0 patent/BRPI0111140B8/pt not_active IP Right Cessation
- 2001-05-22 EG EG20010540A patent/EG24189A/xx active
- 2001-05-22 DE DE60143197T patent/DE60143197D1/de not_active Expired - Lifetime
- 2001-05-22 UA UA20021210537A patent/UA73355C2/uk unknown
- 2001-05-22 CN CNB018101372A patent/CN1227233C/zh not_active Ceased
- 2001-05-22 MX MXPA02011619 patent/MX230696B/es active IP Right Grant
- 2001-05-22 EE EEP200200655A patent/EE05242B1/xx unknown
- 2001-05-22 JP JP2002500844A patent/JP3665053B2/ja not_active Expired - Lifetime
- 2001-05-22 EA EA200201264A patent/EA004809B1/ru not_active IP Right Cessation
- 2001-05-23 SV SV2001000462A patent/SV2002000462A/es active IP Right Grant
- 2001-05-23 HN HN2001000110A patent/HN2001000110A/es unknown
2002
- 2002-03-08 CR CR6606A patent/CR6606A/es unknown
- 2002-10-31 BG BG107237A patent/BG65855B1/bg unknown
- 2002-11-20 IS IS6630A patent/IS2806B/is unknown
- 2002-11-25 HR HR20020934A patent/HRP20020934B1/xx not_active IP Right Cessation
- 2002-11-25 ZA ZA200209558A patent/ZA200209558B/en unknown
- 2002-11-26 NO NO20025674A patent/NO324495B1/no not_active IP Right Cessation
- 2002-12-16 IN IN2089CH2002 patent/IN2002CH02089A/en unknown
- 2002-12-23 MA MA26971A patent/MA26919A1/fr unknown
2004
- 2004-03-10 HK HK04101751A patent/HK1058932A1/xx not_active IP Right Cessation
- 2004-09-10 JP JP2004263913A patent/JP4142621B2/ja not_active Expired - Lifetime
2007
- 2007-11-12 IN IN5103CH2007 patent/IN2007CH05103A/en unknown
2011
- 2011-01-04 CY CY20111100010T patent/CY1111440T1/el unknown

Also Published As

Publication number	Publication date
IL152582A0 (en)	2003-05-29
GT200100091A (es)	2001-12-28
GC0000362A (en)	2007-03-31
SI1296951T1 (sl)	2011-01-31
BRPI0111140B1 (pt)	2018-03-13
MXPA02011619A (es)	2003-03-27
DK1296951T3 (da)	2011-01-24
IN2007CH05103A (fr)	2008-08-27
MX230696B (es)	2005-09-19
JP2005047927A (ja)	2005-02-24
NO20025674L (no)	2002-11-26
NO324495B1 (no)	2007-10-29
AU2001264804B2 (en)	2006-04-06
IS6630A (is)	2002-11-20
CY1111440T1 (el)	2015-08-05
SK287174B6 (sk)	2010-02-08
CA2410234C (fr)	2008-05-13
YU89402A (sh)	2005-11-28
CN1227233C (zh)	2005-11-16
EG24189A (en)	2008-10-08
NO20025674D0 (no)	2002-11-26
EP1296951B1 (fr)	2010-10-06
PT1296951E (pt)	2010-12-07
EA004809B1 (ru)	2004-08-26
CA2410234A1 (fr)	2001-12-06
HN2001000110A (es)	2002-03-06
JO2216B1 (en)	2004-10-07
NZ522394A (en)	2004-05-28
KR100757699B1 (ko)	2007-09-13
GEP20053492B (en)	2005-04-25
IN2002CH02089A (fr)	2005-02-25
IS2806B (is)	2012-09-15
CZ20023888A3 (cs)	2003-02-12
HRP20020934A2 (en)	2005-02-28
HK1058932A1 (en)	2004-06-11
PH12001001175B1 (en)	2006-08-10
EE200200655A (et)	2004-08-16
HU228423B1 (en)	2013-03-28
PA8516901A1 (es)	2002-04-25
BRPI0111140B8 (pt)	2021-05-25
MA26919A1 (fr)	2004-12-20
CN1443168A (zh)	2003-09-17
BG65855B1 (bg)	2010-03-31
ME00428B (me)	2011-10-10
ATE483687T1 (de)	2010-10-15
HUP0302336A2 (hu)	2003-11-28
PE20011324A1 (es)	2002-01-28
WO2001092230A1 (fr)	2001-12-06
JP3665053B2 (ja)	2005-06-29
BG107237A (bg)	2003-05-30
JP2004501116A (ja)	2004-01-15
ES2351958T3 (es)	2011-02-14
KR20030003762A (ko)	2003-01-10
EA200201264A1 (ru)	2003-04-24
DE60143197D1 (de)	2010-11-18
PL358153A1 (en)	2004-08-09
HRP20020934B1 (en)	2012-01-31
TWI303634B (en)	2008-12-01
EE05242B1 (et)	2009-12-15
EP1296951A1 (fr)	2003-04-02
JP4142621B2 (ja)	2008-09-03
MY123569A (en)	2006-05-31
ZA200209558B (en)	2003-10-28
AU6480401A (en)	2001-12-11
AR028577A1 (es)	2003-05-14
SK16702002A3 (sk)	2003-05-02
BR0111140A (pt)	2005-01-11
CR6606A (es)	2006-02-06
SV2002000462A (es)	2002-03-08
RS51541B (sr)	2011-06-30

Publication	Publication Date	Title
UA73355C2 (en)	2005-07-15	5-chlorine-3(4-methanesulfonylphenyl)-6'-methyl-[2,3']pyridinyl in pure crystallyne shape and a method for synthesis
ES2611077T3 (es)	2017-05-04	Forma solida de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il) ciclopropanocarboxamida)-3-metilpiridin-2-il) benzoico
AU2001264804A1 (en)	2002-02-28	5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- [2,3']bipyridinyl in pure crystalline form and process for synthesis
EP2268625B1 (fr)	2012-05-16	Dérivés d'acide carboxylique à substitution oxo-hétérocyclique, et leur utilisation
DK2427425T3 (en)	2017-06-12	tetracycline
JP2018527328A (ja)	2018-09-20	置換３−（３−アニリノ−１−シクロヘキシル−１ｈ−ベンズイミダゾール−５−イル）プロパン酸誘導体を調製する方法
US6521642B2 (en)	2003-02-18	5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl in pure crystalline form and process for synthesis
AU2001292907A1 (en)	2003-05-08	5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl in pure crystalline form and process for synthesis
JP2017537957A (ja)	2017-12-21	置換されたピリジル−シクロアルキル−カルボン酸類、それらを含む組成物およびそれらの医学的使用
US6800647B2 (en)	2004-10-05	5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3]bipyridinyl in pure crystalline form and process for synthesis
AU2007267671A1 (en)	2007-12-06	Salts and crystal modifications thereof